Ranganath Nischal, Tabaja Hussam, Nair Vaisak O, Dumais Mitchell, Stevens Ryan W, Kind Dalton, Lemahieu Allison, O'Horo John, Shah Aditya
Division of Public Health, Infectious Diseases, and Occupational Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Division of Hospital Internal Medicine, Mayo Clinic, Rochester, MN, USA.
J Antimicrob Chemother. 2025 Jul 1;80(7):2016-2024. doi: 10.1093/jac/dkaf168.
To compare the efficacy and safety of antibiotic lock therapy (ALT) versus catheter removal in managing central vascular catheter-associated bloodstream infection (CVC-BSI).
We conducted a single-centre, retrospective cohort study of adult patients treated with ALT or catheter removal for management of CVC-BSI between 2018 and 2022. The primary outcome was a composite of 90 day microbiological relapse or recurrent BSI. Secondary outcomes included 30 day mortality, CVC-associated complications and Clostridioides difficile infection (CDI). Logistic regression with propensity score-adjustment was used to evaluate differences in outcomes and identify predictors of relapse.
During the study period, 106 participants received ALT and 181 underwent catheter removal. Patients treated with ALT received shorter courses of systemic antimicrobials (11 versus 14 days; P < 0.001) and had shorter hospital stays (4 versus 10 days; P < 0.001). Median duration of catheter salvage in patients receiving ALT was 28 days (IQR 7-80). Primary composite outcome was similar between both groups, but ALT was associated with a significantly higher risk of microbiological relapse within 90 days (20% versus 7%; adjusted odds ratio 3.93, 95% CI 1.64-9.40; P = 0.002). No significant difference in 30 day mortality, CVC-related complications or CDI was observed. CoNS BSI was an independent predictor of microbiological relapse in patients treated with ALT (OR 2.28; P = 0.05).
Although ALT offers a non-invasive catheter salvage strategy, its association with higher relapse rates, particularly in CoNS BSI, suggests catheter removal should remain the preferred approach when feasible. ALT could be considered a short-term catheter salvage strategy for pathogens with low virulence when used with close surveillance.
比较抗生素封管疗法(ALT)与拔除导管在处理中心血管导管相关血流感染(CVC-BSI)方面的疗效和安全性。
我们对2018年至2022年间接受ALT或拔除导管治疗CVC-BSI的成年患者进行了一项单中心回顾性队列研究。主要结局是90天微生物学复发或复发性BSI的复合指标。次要结局包括30天死亡率、CVC相关并发症和艰难梭菌感染(CDI)。采用倾向评分调整的逻辑回归来评估结局差异并确定复发的预测因素。
在研究期间,106名参与者接受了ALT,181名接受了导管拔除。接受ALT治疗的患者全身抗菌药物疗程较短(11天对14天;P<0.001),住院时间较短(4天对10天;P<0.001)。接受ALT治疗的患者导管挽救的中位持续时间为28天(IQR 7-80)。两组的主要复合结局相似,但ALT与90天内微生物学复发风险显著较高相关(20%对7%;调整后的优势比3.93,95%CI 1.64-9.40;P=0.002)。在30天死亡率、CVC相关并发症或CDI方面未观察到显著差异。凝固酶阴性葡萄球菌BSI是接受ALT治疗患者微生物学复发的独立预测因素(OR 2.28;P=0.05)。
尽管ALT提供了一种非侵入性的导管挽救策略,但其与较高的复发率相关,尤其是在凝固酶阴性葡萄球菌BSI中,这表明在可行的情况下,拔除导管仍应是首选方法。当与密切监测一起使用时,ALT可被视为针对低毒力病原体的短期导管挽救策略。